TrialNature communications2022

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer.

Jieqiong Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.